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Received January 16, 2015; accepted June 2, 2015AbstractBackground: Some recent studies have described the adverse effects of proton pump inhibitors (PPIs). PPI use and colonic diverticulitis are both
associated with bacterial enteric infection and translocation. The aim of this study was to assess the association between PPI use and colonic
diverticulitis.
Methods: We conducted a population-based nested case-control study in part by use of data retrospectively collected from the National Health
Insurance Research Database. Diverticulitis patients were identified using inpatient discharge records with International Classification of
Diseases, Ninth Revision, Clinical Modification codes (562.11 and 562.13), and were recruited as the study cohort. The controls were matched to
the study patients by age, sex, nonsteroidal anti-inflammatory drugs use, laxative use, and index date. The cumulative defined daily dose (DDD)
was estimated as the sum of the dispensed DDD of any PPI. The adjusted odds ratio and 95% confidence interval (CI) were estimated using
multiple logistic regression.
Results: We enrolled 690 patients with acute diverticulitis, along with 2760 patients who comprised the control group. The adjusted odds ratios
for the study cohort compared with PPI nonusers, after adjusting for possible confounders (including sex, age, comorbidities, and medication),
were 1.29 (95% CI ¼ 0.70e2.36) and 1.02 (95% CI ¼ 0.59e1.76) for the group with cumulative PPI use 42 and 55 DDDs over an exposure
period of 90 and 180 days, respectively, prior to the claimed date of hospitalization for colonic diverticulitis.
Conclusion: The study showed that use of PPIs did not increase the risk of colon diverticulitis.
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The incidence of both asymptomatic and symptomatic
colonic diverticulosis is increasing.1 However, only 10e20%
of patients with diverticulosis develop diverticulitis.2 Factors
such as physical inactivity, constipation, obesity, smoking, and
the use of nonsteroidal anti-inflammatory drugs (NSAIDs)
have been associated with an increased risk of diverticular
disease.3ociation. All rights reserved.
6 B.-L. Ho et al. / Journal of the Chinese Medical Association 79 (2016) 5e10Proton pump inhibitors (PPIs) are primary agents for the
treatment of gastroduodenal ulcers and gatroesophageal reflux
disease and are effective in preventing NSAID/aspirin-
associated peptic ulcer and ulcer bleeding.4 PPIs are among
the most frequently prescribed classes of medications world-
wide because of their high rate of efficacy and low toxicity.5
However, PPIs have recently been reported to produce
adverse effects.6e8 PPIs can interact with targets other than the
gastric Hþ/Kþ ATPase. Colonic epithelial cells, which are
involved in maintaining local electrolyte balance, express
proton pumps in the colon.9 PPIs also influence microbial
growth by inhibiting the colonic HþeKþ ATPase.10
Bacterial colonization by exogenous enteric microbes is
inhibited by host defense mechanisms such as gastric acid,
host gut microflora, local gut immunity, intestinal motility,
intestinal secretion, and the epithelial barrier.11 PPI use4,12 and
colonic diverticulitis13 are both associated with bacterial
enteric infection and translocation. The relationship between
PPI use and diverticulitis is not well documented. Therefore,
we assessed the association between PPI use and colonic
diverticulitis by conducting a nested case-control study based
on the National Health Insurance Research Database (NHIRD)
in Taiwan.
2. Methods2.1. Ethics statement2000-2010All data that could be used to identify patients were
encrypted in the National Health Insurance (NHI) files used in
our study. The confidentiality of the data presented in our
study, which was approved by the Taiwan's National Health
Research Institute (NHRI), adheres to the regulations of the
Bureau of National Health Insurance (BNHI), Taiwan. This
study was also approved by the Institutional Review Board
(IRB) of Taipei City Hospital (IRB No. TCHIRB-1021103-E).
Written consent was waived by the IRB.Based on inpatient discharge records of
colonic diverticulitis (N=1,510)2.2. Data sourceExcludes:
1. Without CT, MRI, colonoscopy, barium 
enema radiological examination (N=765)
2. Patients were under age 20 years (N=4)
3. Patients with prior colectomy, IBD, Celiac 
disease, and colon cancer (N=51)This nationwide cohort study was based on patient data
obtained from the NHIRD, which is managed by the Taiwan
NHRI. The NHIRD contains healthcare data for 99% of Tai-
wan's population (approximately 23 million).14 The sample
files of NHIRD contained comprehensive enrollment and
drug-use information for a randomly selected sample of
1,000,000 NHI beneficiaries, representing approximately 5%
of all enrollees in the year 2000. We used the International
Classification of Diseases, Ninth Revision, Clinical Modifi-
cation (ICD-9-CM) to define diseases.Enrolled:
Colonic diverticulitis patients
Four control patients by using data from 
inpatient medical databases were selected to 
match each newly recorded acute 2.3. Identification of cases and control(N=690)
diverticulitis patient, stratified for age, sex, 
NSAID users, and laxative drugs users, 
within the same observational period
(N=2,760)
Fig. 1. Flowchart depicting the selection of participants.We conducted a population-based nested case-control
study. Diverticulitis patients were identified from the
NHIRD by using inpatient discharge records based on ICD-9-
CM codes (562.11 and 562.13) following computedtomography, magnetic resonance imaging, colonoscopy, and
barium radiological examination between January 1, 2000 and
December 31, 2010. Patients under 20 years of age and pa-
tients with prior colonectomy, celiac disease, and inflamma-
tory bowel disease were excluded. We also excluded patients
diagnosed with colonic cancer between January 1, 1996 and
the index date. Control group patients did not have the code
ICD-9-CM: (562.xx) in their inpatient records or in the
ambulatory-care claims. Four control patients were selected
using data from inpatient medical databases to match each
newly recorded colonic diverticulitis patient by conducting
random sampling stratified by age, sex, NSAID use, and
laxative use in the same observational period. Fig. 1 illustrates
a flowchart of the patient selection process.2.4. Determination of medication exposure for PPIs
2.4.1. Exposure assessment
Information on the prescribed drugs was extracted from the
NHRI prescription database, and the defined daily doses
(DDDs) recommended by the World Health Organization were
used to quantify the use of PPIs.15 The cumulative DDD was
estimated as the sum of the dispensed DDD of any PPI
(omeprazole, lansoprazole, pantoprazole, rabeprazole, or eso-
meprazole) with the final dose taken within the specified
period prior to the index date. The gathered data comprised the
date of prescription, daily dosage, and the number of days of
drug use.
2.4.2. Drug exposure data
We defined current users as patients exposed to PPIs for 28
days prior to the claimed date of hospitalization for acute
diverticulitis. We defined previous users as patients who
experienced PPI exposure between January 1, 2000 and the
Table 1
Characteristics of participants admitted with acute diverticulitis and matched
controls.
Variables Control Diverticulitis p
n ¼ 2760 % n ¼ 690 %
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excluding the current users. Patients with no prescription for
any PPIs at any time between January 1, 2000 and the claimed
date of hospitalization for colonic diverticulitis were defined
as nonusers.Sex >0.99
Male 1492 54.06 373 54.06
Female 1268 45.94 317 45.94
Age (y) >0.99
20e49 844 30.58 211 30.58
50e69 944 34.20 236 34.20
70 972 35.22 243 35.22
Comorbidities
CAD 1437 52.07 370 53.62 0.464
CVD 543 19.67 121 17.54 0.203
DM 570 20.65 161 23.33 0.145
COPD 656 23.77 162 23.48 0.873
Dyslipidemia 661 23.95 129 18.70 0.003
Peptic ulcer 476 17.25 156 22.61 0.001
Medication use
NSAIDs 808 29.28 202 29.28 >0.99
Laxative drugs 1056 38.26 264 38.26 >0.99
Aspirin 333 12.07 243 35.22 <0.001
COX-2 inhibitors 322 11.67 278 40.29 <0.001
Antidiarrhea drugs 492 17.83 427 61.88 <0.001
Steroids 209 7.57 47 6.81 0.495
PPIs 0.025
Nonusers 2248 81.45 531 76.96
Current users 75 2.72 21 3.04
Previous users 437 15.83 138 20.002.5. Assessment of cofounders and covariates
2.5.1. Comorbid illness
Conditions that required inpatient care or three or more
ambulatory-care visits between January 1, 1996 and the index
date of the study were defined as comorbidities. The comor-
bidities identified in our cohort and their corresponding ICD-
9-CM diagnosis codes are listed as follows: coronary artery
disease (ICD-9-CM 410e414), cerebral vascular disease
(ICD-9-CM 430e438), dyslipidemia (ICD: 272.xx), chronic
obstructive pulmonary disease (ICD-9-CM 490e492, 494, and
496), diabetes mellitus (DM; ICD-9-CM 250), and peptic ul-
cers (ICD-9-CM 531, 532, and 533).
2.5.2. Use of other medications
Patients were defined as users of NSAIDs, laxatives,
aspirin, cyclooxygenase-2-specific inhibitors, steroids, and
antidiarrhea drugs based on whether they had consumed the
prescribed medication within 28 days prior to the claimed date
of hospitalization for colonic diverticulitis.CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pulmonary
disease; COX-2 inhibitors ¼ cyclooxygenase-2 specific inhibitors;2.6. Statistical analysis
CVD ¼ cerebral vascular disease; DM ¼ diabetes mellitus;
NSAIDs ¼ nonsteroidal anti-inflammatory drugs; PPIs ¼ proton pump
inhibitors.For comparing the proportions, chi-square statistics was
used. A conditional logistic regression model was used to
estimate the relative magnitude in relation to the use of PPIs.
Exposure was defined as receiving PPIs between January 1,
2000 and the index date. Patients were categorized into one of
the three PPIs exposure categories for analysis: nonusers,
previous users, and current users. In the analysis, participants
were categorized into PPI use below the median (<42 or <55
DDD) and PPI use equal or above the median (42 or 55
DDD) over an exposure period of 90 and 180 days, respec-
tively, prior to the claimed date of hospitalization for colonic
diverticulitis. Patients with no exposure were used as the
reference for calculating odds ratios (ORs) and their 95%
confidence intervals (CIs). Models with and without adjusted
variables were presented. All statistical analyses were per-
formed using the SAS System for Windows, version 9.2 (SAS
Institute, Cary, NC, USA).
3. Results
We enrolled 690 patients with acute diverticulitis, as well as
2760 patients who comprised the control group, based on
NHIRD records from 2000 to 2010. Table 1 displays the de-
mographic data including age, sex, comorbidities, and medi-
cations. Patients with colonic diverticulitis had a considerably
low rate of dyslipidemia, but increased rates of peptic ulcer,
aspirin use, cyclooxygenase-2 inhibitor use, and antidiarrhea
drug use.Compared with PPI nonusers, the crude ORs were 1.12
(95% CI ¼ 0.69e1.84) and 1.34 (95% CI ¼ 1.08e1.67) for
current users and previous users, respectively. However, after
adjusting for possible confounders (including sex, age,
comorbidities, and medication), the adjusted ORs were 0.90
(95% CI ¼ 0.48e1.72) and 1.01 (95% CI ¼ 0.84e1.43) for
the current users and previous users, respectively (Table 2).
When PPI use was categorized by cumulative dosage, the
crude ORs were 0.99 (95% CI ¼ 0.60e1.62) and 1.10 (95%
CI ¼ 0.73e1.67) for the groups with cumulative PPI use of
<42 and <55 DDDs, respectively, and 1.67 (95%
CI ¼ 1.04e2.68) and 1.40 (95% CI ¼ 0.91e2.17) for the
groups with cumulative PPI use of 42 and 55 DDDs over
an exposure period of 90 and 180 days, respectively, prior to
the claimed date of hospitalization for acute diverticulitis,
compared with PPI nonusers. However, after adjusting for
possible confounders (including sex, age, comorbidities, and
medication), the adjusted ORs were 0.79 (95%
CI ¼ 0.44e1.42) and 0.93 (95% CI ¼ 0.56e1.53) for the
groups with cumulative PPI use of <42 and <55 DDDs,
respectively, and 1.29 (95% CI ¼ 0.70e2.36) and 1.02 (95%
CI ¼ 0.59e1.76) for the groups with cumulative PPI use of
42 and 55 DDDs over an exposure period of 90 and 180,
days, respectively, prior to the claimed date of hospitalization
for colonic diverticulitis (Table 2). In addition, values of 1.28
Table 2
Association between exposure to PPIs and acute diverticulitis.
Exposure Cases
Exposed/unexposed
Controls
Exposed/unexposed
Crude OR
(95% CI)
Adjusted ORa
(95% CI)
Current use 21/669 75/2685 1.12 (0.69e1.84) 0.90 (0.48e1.72)
Previous use 141/528 451/2234 1.34 (1.08e1.67) 1.01 (0.84e1.43)
PPI use within 90 d preceding index date
<42 DDDs 20/670 83/2677 0.99 (0.60e1.62) 0.79 (0.44e1.42)
42 DDDs 25/665 61/2699 1.67 (1.04e2.68) 1.29 (0.70e2.36)
PPI use within 180 d preceding index date
<55 DDDs 30/660 111/2649 1.10 (0.73e1.67) 0.93 (0.56e1.53)
55 DDDs 28/662 81/2679 1.40 (0.91e2.17) 1.02 (0.59e1.76)
CAD ¼ coronary artery disease; CI ¼ confidence interval; COPD ¼ chronic obstructive pulmonary disease; COX-2 inhibitors ¼ cyclooxygenase-2 specific in-
hibitors; CVD ¼ cerebral vascular disease; DM ¼ diabetes mellitus; NSAIDS ¼ nonsteroidal anti-inflammatory drugs; OR ¼ odds ratio.
a Adjusted for matching variables such as comorbidities (including CAD, CVD, dyslipidemia, COPD, DM, and peptic ulcer) and medications (including
NSAIDs, laxative drugs, aspirin, COX-2 inhibitors, antidiarrhea drugs, and steroids).
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DM patients, 1.30 (95% CI ¼ 1.04e1.61) and 1.31 (95%
CI ¼ 1.05e1.63) for peptic ulcer patients, and 1.47 (95%
CI ¼ 1.22e1.77) and 1.47 (95% CI ¼ 1.22e1.78) for anti-
diarrhea medication users, were recorded over an exposure
period of 90 and 180 days, respectively, prior to the claimed
date of hospitalization for colonic diverticulitis (Table 3).
4. Discussion
This clinical epidemiological study is the first of its kind
that focuses exclusively on inpatients with colonic diverticu-
litis who receive PPIs. The nationwide population-based,
nested case-control study did not reveal that use of PPI
significantly increased the risk of colon diverticulitis after
adjustment for possible confounding factors. Factors such asTable 3
Independent predictors of acute diverticulitis among all the enrollees by
conditioned logistic regression model.
Variables PPI use within 90 d PPI use within 180 d
OR (95% CI) OR (95% CI)
Comorbidities
CAD 1.13 (0.90e1.42) 1.13 (0.90e1.42)
CVD 0.86 (0.66e1.10) 0.85 (0.66e1.10)
DM 1.28 (1.01e1.61) 1.27 (1.01e1.60)
COPD 0.93 (0.75e1.16) 0.93 (0.75e1.16)
Dyslipidemia 0.64 (0.51e0.81) 0.65 (0.51e0.82)
Peptic ulcer 1.30 (1.04e1.61) 1.31 (1.05e1.63)
Medication use
Aspirin 0.89 (0.71e1.11) 0.89 (0.71e1.11)
COX-2 inhibitors 1.16 (0.94e1.42) 1.15 (0.94e1.41)
Antidiarrhea drugs 1.47 (1.22e1.77) 1.47 (1.22e1.78)
Steroids 0.86 (0.61e1.21) 0.86 (0.61e1.21)
PPIs use within 90 d preceding index date
<42 DDD vs. nonusers 0.79 (0.44e1.42)
42 DDD vs. nonusers 1.29 (0.70e2.36)
PPIs use within 180 d preceding index date
<55 DDD vs. nonusers 0.93 (0.56e1.53)
55 DDD vs. nonusers 1.02 (0.59e1.76)
CAD ¼ coronary artery disease; CI ¼ confidence interval; COPD ¼ chronic
obstructive pulmonary disease; COX-2 ¼ cyclooxygenase-2; CVD ¼ cerebral
vascular disease; DM ¼ diabetes mellitus; OR ¼ odds ratio.constipation and NSAIDs have been associated with an
increased risk of colonic diverticulitis.3 Therefore, four control
patients were selected to match colonic diverticulitis case
stratified by laxative drugs use and NSAID use.
Current long-term PPI therapy has been associated with the
induction of severe hypomagnesemia, iron and vitamin B12
deficiency, community-acquired pneumonia, hip fracture, and
interstitial nephritis.16 Elevation in gastric pH levels may exert
deleterious effects on the gastrointestinal host defense
including delayed gastric emptying, increased bacterial
translocation, decreased gastric mucus viscosity, and changes
in the normal microbial flora.17 The pathogenesis of divertic-
ulitis involves an altering of the gut flora13 and a stasis or
obstruction in the narrow-necked pseudodiverticulum leading
to bacterial overgrowth.18 Suppressing gastric acidity may
therefore result in an increased load of pathogenic microbes in
the gastrointestinal tract. However, our current study addresses
the effect of PPIs on colonic diverticulitis and it remains a null
association. PPIs have been implicated in the disruption of the
ecology of the gut and changes in bacterial growth.19 Janar-
thanan et al20 conducted a meta-analysis and suggested that
PPIs increase the incidence of Clostridium difficile infection.
The case-control study conducted by Garcia Rodriguez et al21
revealed an increased incidence of Salmonella and Campylo-
bacter jejuni gastroenteritis in patients taking PPIs. People
with comorbidities (especially elderly patients) are highly
likely to be prescribed acid-suppressive therapy.20 The role of
PPI dosage and duration of use in immunocompetent and
immunocompromised patients who have contracted varying
levels of acute and recurrent diverticulitis requires investiga-
tion. Further study to evaluate whether use of PPI increased
the risk of colon diverticulitis is warranted, especially in
subgroup patients with risks or immune-compromised
patients.
The clinical process of colonic diverticulitis varies in
accordance with the extent of the disease's progress. Because
only 10e20% of patients with diverticulosis develop diver-
ticulitis, proving that these patients have recurrent asymp-
tomatic diverticulitis might be difficult. Therefore, we adopted
a strict definition of the control group, in which a patient
cannot exhibit ICD-9-CM code 562.xx in their inpatient
9B.-L. Ho et al. / Journal of the Chinese Medical Association 79 (2016) 5e10records or in the ambulatory care claims between 2000 and
2010. To be included in the study group, patients were iden-
tified using ICD-9-CM codes following computed tomogra-
phy, magnetic resonance imaging, colonoscopy, and barium
radiological imaging (excluding 765 cases without image ex-
amination). Although imaging reports are unavailable in the
NHIRD, the Bureau of the NHI randomly samples the claims
data from every hospital and reviews charts to verify diag-
nostic validity. ICD-9-CM coding was strictly audited for the
purpose of reimbursement.
Our observations are consistent with those of previous re-
ports regarding the role of DM in diverticulitis, but no such
association was observed for diverticulitis in steroid users.
This study showed that DM is an independent risk factors of
colonic diverticulitis, which is in agreement with Floch's22
study. However, Humes et al23 revealed that perforated
diverticular disease is a severe surgical emergency, and oral
corticosteroids (OR ¼ 2.74; 95% CI ¼ 1.63e4.61) are
strongly associated with an increased risk of perforation. By
contrast, our data suggested that steroid use did not increase
the risk of acute diverticulitis, which is dissimilar to the result
reported by Humes et al.23 The primary discrepancy is the
enrolled patient criteria. Further study is required to elucidate
the role of corticosteroids, including duration and dose in
immune-competent and immunocompromised patients, diag-
nosed with varying extents of diverticulitis.
This study had several limitations. First, factors such as
patients' lifestyles, dietary habits (especially fiber intake),
body mass indices, and smoking were not available for
adjustment.24e26 Second, certain data, such as the location of
diverticulitis, are unavailable in the NHIRD. Left-sided
diverticular disease is most common in Western societies,
whereas right-sided diverticular disease is more prevalent in
Asia. In addition, colonic diverticular disease is not as com-
mon in Asian societies as in Western societies, so the results
cannot be applied to western societies. Third, the consumption
of PPIs could not be confirmed in this study. However, the
Bureau of the NHI has formed various audit committees that
randomly sample claims data from every hospital and review
charts on a regular basis to verify the diagnostic validity and
quality of care. Fourth, the causality of this phenomenon has
not been established by any randomized placebo-controlled
clinical trials. Determining causality is difficult because
neither withholding PPI therapy from those who require it, nor
administering PPIs to those who do not require them are
ethically feasible.20 Therefore, we conducted a nested case-
control study by using data from the Taiwan NHIRD. In Tai-
wan's NHI program, the use of PPIs is strictly limited to
treating patients with reflex esophagitis or peptic ulcer disease
for 4 months after gastroscopic confirmation.27 Therefore, we
analyzed the cumulative dose effect of PPIs on acute diver-
ticulitis for an exposure period of 90 and 180 days prior to the
claimed date of hospitalization for colonic diverticulitis. Fifth,
hospitalization is indicated if the patient is unable to tolerate
oral intake or if the patient has acute diverticulitis. Estab-
lishing a standard definition is crucial; therefore, we analyzed
only the cases requiring hospitalization for colonicdiverticulitis by using data from inpatient medical databases.
The actual prevalence rate of diverticulosis is difficult to
determine because most patients are asymptomatic. Therefore,
we conducted the current study by using the nested case-
control method instead of the cohort study method. Finally,
use of over-the-counter oral PPI medications was not included
in our database.
In conclusion, the study showed that use of PPIs did not
increase the risk of colon diverticulitis. Prospective studies are
necessary to confirm this association in the general population
and explore whether this risk can be reversed by avoiding
unnecessary PPI use and administering the optimal PPI DDD.
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